WO2015160795A1 - Compositions and methods for treating inflammation - Google Patents
Compositions and methods for treating inflammation Download PDFInfo
- Publication number
- WO2015160795A1 WO2015160795A1 PCT/US2015/025730 US2015025730W WO2015160795A1 WO 2015160795 A1 WO2015160795 A1 WO 2015160795A1 US 2015025730 W US2015025730 W US 2015025730W WO 2015160795 A1 WO2015160795 A1 WO 2015160795A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- administering
- patient
- skin
- biologically active
- active portion
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title description 33
- 230000004054 inflammatory process Effects 0.000 title description 14
- 206010061218 Inflammation Diseases 0.000 title description 13
- 102100033502 Interleukin-37 Human genes 0.000 claims abstract description 66
- 101710181554 Interleukin-37 Proteins 0.000 claims abstract description 66
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 16
- 230000000699 topical effect Effects 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000005855 radiation Effects 0.000 claims description 10
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 9
- 208000035143 Bacterial infection Diseases 0.000 claims description 9
- 206010042496 Sunburn Diseases 0.000 claims description 9
- 206010000496 acne Diseases 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 201000004624 Dermatitis Diseases 0.000 claims description 6
- 206010017533 Fungal infection Diseases 0.000 claims description 4
- 206010051246 Photodermatosis Diseases 0.000 claims description 4
- 230000008845 photoaging Effects 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010016936 Folliculitis Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 206010063562 Radiation skin injury Diseases 0.000 claims description 2
- 241001303601 Rosacea Species 0.000 claims description 2
- 241000159243 Toxicodendron radicans Species 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 208000010247 contact dermatitis Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 206010035114 pityriasis rosea Diseases 0.000 claims description 2
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims description 2
- 201000004700 rosacea Diseases 0.000 claims description 2
- 231100000241 scar Toxicity 0.000 claims description 2
- 230000037380 skin damage Effects 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 26
- 239000003795 chemical substances by application Substances 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 16
- 102000004127 Cytokines Human genes 0.000 description 14
- 108090000695 Cytokines Proteins 0.000 description 14
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 241000186427 Cutibacterium acnes Species 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- -1 propylene glycol Chemical class 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 201000004681 Psoriasis Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 208000020154 Acnes Diseases 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000003974 emollient agent Substances 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 239000004909 Moisturizer Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000001333 moisturizer Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000033289 adaptive immune response Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940099417 ceramide 2 Drugs 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 229940107161 cholesterol Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920002675 Polyoxyl Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229940070718 behentrimonium Drugs 0.000 description 2
- YSJGOMATDFSEED-UHFFFAOYSA-M behentrimonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCCCCC[N+](C)(C)C YSJGOMATDFSEED-UHFFFAOYSA-M 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 229940044176 ceramide 3 Drugs 0.000 description 2
- 229940056318 ceteth-20 Drugs 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 229940074979 cetyl palmitate Drugs 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229940100460 peg-100 stearate Drugs 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical class CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 231100000075 skin burn Toxicity 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 235000014692 zinc oxide Nutrition 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- ZQCIPRGNRQXXSK-UHFFFAOYSA-N 1-octadecoxypropan-2-ol Chemical compound CCCCCCCCCCCCCCCCCCOCC(C)O ZQCIPRGNRQXXSK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-N 7-methyloctanoic acid Chemical compound CC(C)CCCCCC(O)=O XZOYHFBNQHPJRQ-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 239000004155 Chlorine dioxide Substances 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000039996 IL-1 family Human genes 0.000 description 1
- 108091069196 IL-1 family Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000008673 Persea americana Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000012658 Skin autoimmune disease Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- WYWZRNAHINYAEF-AWEZNQCLSA-N [(2s)-2-ethylhexyl] 4-(dimethylamino)benzoate Chemical compound CCCC[C@H](CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-AWEZNQCLSA-N 0.000 description 1
- ZXQYGBMAQZUVMI-QQDHXZELSA-N [cyano-(3-phenoxyphenyl)methyl] (1r,3r)-3-[(z)-2-chloro-3,3,3-trifluoroprop-1-enyl]-2,2-dimethylcyclopropane-1-carboxylate Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-QQDHXZELSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- JTBVPHBMCXEPOX-UHFFFAOYSA-N benzoic acid;formaldehyde Chemical compound O=C.OC(=O)C1=CC=CC=C1 JTBVPHBMCXEPOX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940105847 calamine Drugs 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 235000019398 chlorine dioxide Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- SKPLBLUECSEIFO-UHFFFAOYSA-N chlorphenesin carbamate Chemical compound NC(=O)OCC(O)COC1=CC=C(Cl)C=C1 SKPLBLUECSEIFO-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- CMDKPGRTAQVGFQ-RMKNXTFCSA-N cinoxate Chemical compound CCOCCOC(=O)\C=C\C1=CC=C(OC)C=C1 CMDKPGRTAQVGFQ-RMKNXTFCSA-N 0.000 description 1
- 229960001063 cinoxate Drugs 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229940052366 colloidal oatmeal Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- HUVYTMDMDZRHBN-UHFFFAOYSA-N drometrizole trisiloxane Chemical compound C[Si](C)(C)O[Si](C)(O[Si](C)(C)C)CC(C)CC1=CC(C)=CC(N2N=C3C=CC=CC3=N2)=C1O HUVYTMDMDZRHBN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910052864 hemimorphite Inorganic materials 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229960004881 homosalate Drugs 0.000 description 1
- 229940106579 hops extract Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001906 humulus lupulus l. absolute Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- JRKSTJIPGYBLNV-UHFFFAOYSA-N n-[3-[dodecanoyl(2-hydroxyethyl)amino]-2-hydroxypropyl]-n-(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CC(O)CN(CCO)C(=O)CCCCCCCCCCC JRKSTJIPGYBLNV-UHFFFAOYSA-N 0.000 description 1
- PDRAHDYJNDYBNK-UHFFFAOYSA-N n-[3-[hexadecanoyl(2-hydroxyethyl)amino]-2-hydroxypropyl]-n-(2-hydroxyethyl)hexadecanamide Chemical compound CCCCCCCCCCCCCCCC(=O)N(CCO)CC(O)CN(CCO)C(=O)CCCCCCCCCCCCCCC PDRAHDYJNDYBNK-UHFFFAOYSA-N 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 229960003921 octisalate Drugs 0.000 description 1
- 229940066429 octoxynol Drugs 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- WCJLCOAEJIHPCW-UHFFFAOYSA-N octyl 2-hydroxybenzoate Chemical compound CCCCCCCCOC(=O)C1=CC=CC=C1O WCJLCOAEJIHPCW-UHFFFAOYSA-N 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 1
- 229960001173 oxybenzone Drugs 0.000 description 1
- 125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 description 1
- 229960002638 padimate o Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 125000001095 phosphatidyl group Chemical group 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229940078491 ppg-15 stearyl ether Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100459 steareth-20 Drugs 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 239000012749 thinning agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229940025703 topical product Drugs 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 229940030300 trolamine salicylate Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
Definitions
- UV irradiatioii As the largest, organ, human skin provides the first line of defense against microbial pathogen-associated molecular patterns (PAMP) and physical and chemical damage- associated molecular patterns (DAMP).
- UV Ultraviolet
- irradiatioii has profound effects on hitman skin, causing sunburn, inflammation, cellular-tissue injury, photoaging and skin cancer. Most of these effects are mediated by proinflammatory cytokines produced by keratinocytes, such as l.L-6 and iL- .
- Some aspects of the inventio relate to methods for treating, inhibiting, or
- Some embodiments of the invention relate to topical medicaments comprising a dermatologieally acceptable carrier or excipient and interleukin-37, or a biologically active portion thereof
- Figure 1 includes four panels, labeled panels (A), (B), (C), and (D).
- Panel (A) shows that IL-37 is induced in skin cells by P. acnes.
- Panel (B) shows that the immortalized human keraiiiiocvte ceil line HaCaT displays higher expression levels of IL-37 than monocytes in cytosol.
- Panel (C) shows that IL-37 is activated b F. acnes infection.
- Panei (D) shows that IL-37 is expressed at higher level in acnes lesions.
- Figure 2 shows that exogenous IL-37 attenuates P. acnes-induced inflammation in the immortalized human keratinoeyte cell line HaCaT, and figure 2 includes three panels, labeled panels (A), (B), and (C).
- Panel (A) shows that P. acnes induced IL-6 expression in HaCaT in a dose dependent manner
- Panei (B) shows that exogenous IL-37 reduces P. acnes- ' mduecd IL-6 secretion in HaCaT.
- Panel (C) shows thai exogenous IL-37 reduced P. a jey-induced IL-8 secretion in HaCaT.
- Figure 3 shows the anti-inflammatory effects of IL-37 on UVB-induced HaCaT cells, and figure 3 includes four panels, labeled panels (A), (B) compliment fC), and (D).
- Panel (A) shows that UVB induces IL-6 secretion in HaCaT i a dose dependent manner.
- Panel (B) shows that UVB down-regulates IL-37 expression.
- Panel (C) shows that exogenous IL-37
- Panel (D) shows that IL-37 ameliorates inflammation under the different doses of UVB.
- Figure 4 shows that exogenous IL-37 attenuates . acnes- and UVB- induced IL-6 secretion by modulating NFKB p65 phosphorylation and ER signaling pathway, and figure 4 includes three panels, labeled panels (A), (B), and (C).
- Panel (A) shows that IL-37 reduces the phosphorylation of NFtcB p 5 and E K2.
- Panel (B) shows that IL-37 reduces the phosphorylation of NFKB p65 and ERK2 induced by P. acnes.
- Panel (C) shows that IL- 37 reduces the phosphorylation of NFKB p65 and ERK2 induced by UVB radiation.
- Figure 5 shows that IL-18Rp and l ' L-i8B ' Pa are involved in exogenous IL-37 attenuated inflammation induced by UVB and P. acnes, and figure 5 includes three panels, labeled panels (A), (B), and (C).
- Panel (A) shows that IL-37 anti-inflammatory properties are dependent on IL-18Rf ⁇ .
- Panel (B) shows that IL-37 and l ' L-18BPa additively inhibit IL-6 secretion induced by U B.
- Panel (C) shows that l ' L-37 and IL-1 SBPa down-regulate IL-6 secretion induced by P. acnes.
- IL-37 is a potent: inhibitor of immunity by keeping the cytokine equilibrium from excessi ve inflammation, and it has shown broad inhibitory properties in the innate inflammatory and adaptive immune responses.
- IL-37 is a natural suppressor of innate inflammatory and immune responses. It serves as a dual-function cytokine with both intracellular and exiraceiiuiar mechanisms of action (Biila i A.M., et a!,, Proc. Natl Acad. Sci. U.S.A., 1 i 1(7):2650 (2034)).
- IL-37 is absent in mice, but mice that express huma IL-37 are protected from lipopolysaccharide(LPS)-iiidu:ced shock, and showed markedly improved lung and kidney function and reduced liver damage after exposure to LPS ( okl M.F., et Nature Medicine, 1 1(1 1 ) : 1014 (2010)). Additionally, IL-37 plays a key role in intestinal inflammation because IL-37 expression protects mice from colitis (McNamee E.N., Proc. Natl Acad. Sci. U.S.A., 108(40): 1,671 1 (201 1».
- IL-37 In vivo expression of human iL-37 in mice reduces local and systemic inflammation in ConA-indueed hepatitis and LPS challenge (Bulau A.M., et at, Set. World. J., 1 1 :2480 (20.1 1 ); Sakai ., et a/. , J. Gastroenterol. Hepatol., 27(1): 1609 (201.2)). Additionally, IL-37 is involved in the pathophysiology of inflammatory bowel disease (IBD) as an antiinflammatory cytokine, and it is an inhibitor of both innate and acquired immune responses (!maeda H., et ah, Clin. Exp. Immunol., 172(3):4i0 (2013)). Further, IL-37 ameliorates the inflammatory process in psoriasis by suppressing pro-inflammatory cytokine expression (Teng ., J. Immunology, 192(4); 1815 (2014».
- IBD inflammatory bowel disease
- IL-37 a member of the 11..- 1 famil of cytokines, has recently been shown to act as a potent inhibitor of inflammatory response. Skin tissue staining shows that IL-37 is present in high concentrations in epidermal keratinoeytes and in even higher quantities in chronic immune-mediated skin diseases, as psoriasis. As IL-37 is concentrated in the outer most layers of the skin, this cytokine may be important in the skin as a block to hyper reactive immunity.
- the immortalized human keratmocyte cell line HaCaT does not actively secrete IL-37, but contains high cytosoiic concentrations of IL-37 ( Figure l b).
- IL-37 is also an inducible cytokine as its gene expression increases at least 60% after treatment with P. acnes and UVB (p 0.05) and is upregulated in acne lesions (p ⁇ 0.0 i ).
- the active spliced form of recombinant IL-37 inhibited UVB and P. acnes induction of T F-a, IL- ⁇ , and IL-6. This suggests that IL-37 has an anti-inflammatory role in response to damage- and pathogen-associated molecular patterns in keratinoeytes.
- interleukin-37 IL-37
- IL-37 interleukin-37
- IL-1 IL-1 family of cytokines
- IL-37 has a significant role in the regulation of inflammation and would healing as a result of both pathogenic and damage-rela ted stimuli, including i'lOpio h t nm acnes infection and ultraviolet B radiation.
- IL-37 was found to be expressed at high concentrations in the epidermis, and it is both expressed and translated by keratinocytes. While this data suggests that active IL-37 is not actively secreted b keratinocytes in high concentrations, the active protein is present in relati vely high concentrations intraccllularly in
- IL-37 in the presence of both *. acnes infection and UVB radiation are able to significantly reduce the induction of pro-inflammatory cytokines, including IL-6, and decrease the activation of nuclear factor kappa b (NFKB) and mitogen- aetivated protein kinases signaling. These latter signaling pathways have been shown to be tremendously important in the regulation of turaorigenesis and immune regulation.
- IL-37 significantly nioduiates the expression of matrix metailoprofeinase 3 in a direction that correlates with improved clinical outcomes of scarring.
- recombinant IL-37 can be administered for the prevention and treatment of infectious and damage-induced inflammatory skin diseases, autoimmune diseases, cancers, and to improve outcomes of scarring and wound healing.
- a or “an” may mean one or more.
- the words “a” or “an” when used in conjunction with the word “comprising” , the words “a” or “an” may mean one or more than one.
- another may mean at least a second or more.
- IL-ISBPa refers to DL-18 binding protein isoform a.
- prophylactic or ' ' therapeutic' treatment is art-recognized and includes administration to the host- of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic (i.e. , it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
- the unwanted condition e.g., disease or other unwanted state of the host animal
- preventing is art-recognized, and when used in relation to a condition such as a local recurrence (e.g., blemish), a disease such as acne or psoriasis, or an injury such as sunburn, is wel! understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition.
- prevention of acne includes, for example, reducing the number of detectable blemishes (i.e.
- Preven tion of psoriasis includes, for example, reducing the magnitude and/or frequency of lesions experienced by subjects in a treated population versus an untreated control population.
- Prevention of a sunburn includes, for example, reducing the severit of a sunburn.
- radiation burn re ers to tissue burns (esp, skin burns) caused by thermal radiation, radio frequency energy, microwaves, ultraviolet light, x-rays, ionizing radiation, gamma radiation.
- '"sunburn refers to tissue bums (esp, skin burns) caused by exposure to ultraviolet radiation.
- a "therapeutically effective amount" of a compound with respec t to the subject method of treatment refers to an amount of the compound! s) in a preparation which, when administered as part of a desired dosage regimen ⁇ to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, eg,, at a reasonable benefit/risk ratio applicable to any medical treatment.
- the term “'treating” or “treatment * includes reversing, reducing, or arresting die symptoms, clinical signs, and underlying pathology of a condition in a manner to improve or stabilize a subject's condition.
- Suitable topical vehicles and vehicle components for use with the formulations of the invention are well known in the cosmetic and pharmaceutical arts, and include such vehicles (or vehicle components) as water; organic solvents such as alcohols (particularly lower alcohols readily capable of evaporating from the skin such as ethanol), glycols (such as propylene glycol, butylenc glycol, and glycerol (glycerin)), aliphatic alcohols (such as lanolin); mixtures of water and organic solvents (such as wa ter and alcohol ), and mixtures of organic solvents such as alcohol and glycerol (optionally also with water); lipid-based materials such as fatty acids, acylglycerols (including oils, such as mineral oil, and fats of natural or synthetic origin), phosphogSycerides, sphingoiipids and waxes; protein- based materials such as collagen and gelatin; si!icone-based materials (both non-volatile and volatile) such as cyclomediicone, dimediicono
- hydrocarbon-based materials such as petrolatum and squalane
- other vehicles and vehicle components that arc suitable for administration to the skin, as well as mixtures of topical vehicle components as identified above or otherwise known to the art
- compositions of the present invention are oil-in- water emulsions.
- Liquids suitable for use in formulating compositions of the present invention include water, and water-miscible solvents such as glycols (e.g. , ethylene glycol, butylene glycol, isoprene glycol, propylene glycol), glycerol, liquid po!yols, dimethyl sulfoxide, and isopropyl alcohol
- glycols e.g. , ethylene glycol, butylene glycol, isoprene glycol, propylene glycol
- glycerol glycerol
- liquid po!yols dimethyl sulfoxide
- isopropyl alcohol isopropyl alcohol
- formulations without methanol, ethanol, propanols, or butano!s are desirable.
- lipid-like (oily or fatty) or lipophilic ingredients do not uniformly disperse in aqueous solvents unless they are first combined with eraulsifiers, which form microscopic aqueous soluble structures (droplets) that contain a lipophilic interior and a hydrophilic exterior, resulting in an oil-in-water emulsion.
- eraulsifiers which form microscopic aqueous soluble structures (droplets) that contain a lipophilic interior and a hydrophilic exterior, resulting in an oil-in-water emulsion.
- a molecule In order to be soluble in aqueous media, a molecule must be polar or charged so as to favorably interact with water molecules, which are also polar.
- an emulstfier which forms stable structures that contain the hydrophilic components in the interior of the structure while the exterior is lipophilic so that it can dissolve in the lipophilic solvent to form a water-io-oil emulsion. It is well known that such emulsions can be destabilized by the addition of salts or other charged ingredients which can interact with the polar or charged portions of the emulsifier within an emulsion droplet. Emulsion destabiiizatiort results in the aqueous and lipophilic ingredients separating into two layers, potentially destroying the commercial value of a topical product.
- Surfactants suitable lor use in the present invention m y be ionic or non-ionic. These include, but are not limited to: ceryi alcohol, polysorbates (Polysorbate 20,
- Polysorbate 40 Polysorbate 60, Polysorbate SO), steareth-10 (Brij 76), sodium dodecyl sulfate (sodium lauryl sulfate), lauryl dimethyl amine oxide, cety!trimethylamraooiura bromide (CTAB), polyethoxylated alcohols, polyoxyethylcne sorbitan, octoxynol, N,N- dimethyidodecylamine-N-oxide, feexadecyUrimethylammonium bromide (HTAB), polyoxyl 10 lauryl ether, bile salts (such as sodium deoxyeholate or sodium chelate), polyoxyl castor oil, nonylphenol ethox late, eyclodextrins, lecithin, dimethicone copolyol, lauramid ⁇ DEA, coeamide DBA, cocamide MEA, ofeyf betaine, cocamid
- ceteth-10 is the polyethylene glycol ether of cetyl alcohol where » has art average value of 10; ceteth- 10 phosphate is a mixture of phosphoric acid esters of ceteth-1 ), eeteth-20, Brij S10 (polyethylene glycol octadecyl ether, average M n ⁇ 71 1), and Poioxamers (including, but not limited to, Poloxaracr 188 (HO(C 2 H 4 O CH(C3 ⁇ 4)CH20 C2H40 ' ) a H 5 average molecular weight 8400) and Poloxaracr 407 ⁇ HO(C23 ⁇ 40) a (CH(CH; ; CH 2 0 b (C 2 H 4 0) a H, wherein a is about 101 and h is about 56)).
- Appropriate combinations or mixtures of such surfactants may also be used according to the present invention.
- emulsifiers may also serve as emulsifiers in formulations of the present invention.
- suitable emu!stfiers for use in the formulations of the present invention include, but are not limited to, behentrimonium methositlfate-cetearyi alcohol, non-ionic emii!sifiers !ike emulsifying wax, polyoxyethylene oleyl ether, PEG-40 stearate, eetostearyl alcohol (cetearyl alcohol), ceteareth-12, ceteareth-20, eeteareth ⁇ 30, ceteareth alcohol, Ceteth-20 (Ceteth-20 is the poly ethylene glycol ether of cetyl alcohol where n has an average value of 20), oleic acid, oie i alcohol, glyceryl stearate, PEG-75 stearate, PEG- 100 stearate, and PEG- 100 stearate, ceramide 2, ceramide
- Suitable moisturizers for use in the formulations of the present invention include, but are not limited to, lactic acid and other hydroxy acids and their salts, glycerol, propylene glycol, butyiene glycol, sodium PCA, sodium hyaluronate, Carbowax 200, Carbo ax 400, and Carbowax 800,
- Suitable emollients or humeetaiits for use in the formulations of the present invention include, but are not limited to, panthenol, cetyl palmitate, glycerol (glycerin), PPG-15 stearyl ether, lanolin alcohol, lanolin, lanolin derivatives, cholesterol, petrolatum, isostearyS neoperttartoate, oetyl stearate, mineral oik isocetyl stearate, myristyi myristate, oetyl dodecanoL 2-ethylhexyi palmitate (oetyl palmitate), dimethieone, phenyl
- giycyrrhetinic acid safllower oil, olcyl alcohol, oleic acid, stearic acid. dicapryiate/dicaprate,, diethyl sehacate, isostearyl alcohol, pentylene glycol, isononyi isononanoate, and l,3-bls(N ⁇ 2-(hydroxyethy1)palmuoylamino)-2-hydroxypropane.
- composition may further include components adapted to improve the stability or effectiveness of the applied formulation.
- Suitable preservatives for use in the present invention include, but are not limited to: ureas, such as i idazolidinyi urea and diazotidioyl urea; phenoxyeihanoi; sodium methyl parahen, methy!paraben, ethylparaben, and propylparaben; potassium sorbate; sodium benzoate; sorbic acid; benzoic acid; formaldehyde; citric acid; sodium citrate; chlorine dioxide; quaternary ammonium compounds, such as benzalkomum chloride, benzethonium chloride, eetrimidc, deqimhn um chloride, and eetyipyridinium chloride; mercurial agents, such as phenylmereurie nitrate, phenylmereurie acetate, and thimerosal; piroctone olamine; Viiis vinifem seed oil; and alcoholic agents, for example, chlorobut
- Suitable antioxidants include, but are not limited to, ascorbic acid and its esters, sodium bisulfite, butylatcd hydroxytoluene, buty!ated hydroxyamsole, tocopherols, tocophetyi acetate, sodium ascorbaie/ascorbic acid, ascorbyi palmitate, propyl galiate, and chelating agents like EDTA (e.g. , disodium EDTA), citric acid, and sodium citrate.
- EDTA e.g. , disodium EDTA
- the antioxidant or preservative comprises (3-(4- chlorophenoxy)-2-hydroxypropyl carbamate.
- antioxidants or preservatives of the present invention may also function as a moisturizer or emollient, for example.
- composition can also contain any other agent that has a desired effect when applied topically to a mammal, particularly a human.
- suitable classes of active agents include, but are not limited to, antibiotic agents, antimicrobial agents, anti-acne agents, antibacterial agents, antifungal agents, antiviral agents, steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, anesthetic agents, antipiitriginous agents, antiprotozoal agents, anti-oxidants, antihistamines, vitamins, and hormones. Mixtures of an of these active agents may also be employed Additionally, dermatoiogicaliy-acceptable sails and esters of any of these agents may be employed.
- Suitable buffer sails are well-known in the art.
- suitable buffer salts include, but are not limited to sodium: citrate, citric acid, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, and potassium phosphate tribasic.
- Suitable viscosity adjusting agents for use in the formulations of the present invention include, but are not limited to, protective colloids or non-ionic gums such as hydroxyethyleeiluiose, xanthan gum, and sclerotiura gum, as well as magnesium aluminum: silicate, silica, macrocrystalline wax, beeswax, paraffin, and cetyl palmitate. in addition, appropriate combinations or mixtures of these viscosity adjusters may be utilized according to the present invention.
- Additional constituents suitable for incorporation into the emulsions of the present invention include, but are not limited to: skin protectants, adsorbents, demulcents, emollients, moisturizers, sustained release materials, solubilizing agents, skin-penetration agents, skin soothing agents, deodorant agents, antiperspirants sun screening agents, sunless tanning agents, vitamins, hair conditioning agents, anti-irritants, anti-aging agents, abrasives, absorbents, auti-caking agents, anti-static agents, astringents (e.g..).
- witch hazel, alcohol, and herbal extracts such as chamomile extract
- bmders/excipiems buffering agents
- chelating agents e.g., citric acid, sodium hydroxide, and sodium phosphate
- pH adjusters e.g., citric acid, sodium hydroxide, and sodium phosphate
- lipids normally found in healthy skin may be incorporated into the emulsions of the present invention, in certain embodiments, the Itpid is selected from the group consisting of ceramtdes, cholesterol, and free fatty acids.
- examples of lipids include, but arc not limited to, eeramide 1, ceramide 2, eeramide 3, eeramide 4, eeramide 5, eeramide 6, hyd oxypropyl bispa.hnitam.ide MEA, and
- hydroxy-propyl bislauramide MBA examples include paimitoyl dipeptide-5 diaminohutyloyl hydro y threonine and paimitoyl dipeptide-6 diaim ' nohydroxybutyrate.
- Examples of skin soothing agents include, but are not limited to algae extract, mugwort extract, stearyi glycyrrhetinate, bisabolol, allantoic aloe, avocado oik green tea extract, hops extract, chamomile extract, colloidal oatmeal, calamine, cucumber extract, and combinations thereof.
- compositions comprise bergamot or bergamot oil.
- Bergamot oil is a natural skin toner and detoxtiier. In certain embodiments, it may prevent premature aging of skin and may have excellent effects on oily skin conditions and acne.
- vitamins examples include, but are not limited to, vitamins A, ⁇ E, K, and combinations thereof.
- Vitamin analogues are also contemplated; for example, the vitamin D analogues eaieipotnene or caicipotriol.
- the vitamin may be present as teirahexyldecyS ascorbate.
- This compound exhibits antioxidant activity, inhibiting lipid peroxidation, hi certain embodiments, use can mitigate the damaging effects ofUV exposure. Studies have shown it to stimulate collagen production as well as clarifying and brightening the skirt by inhibiting meianogenesis (the -production of pigment) thereby promoting a more even skin tone.
- sunscreens include, but are not limited to, p-aramobmzoic acid, avobenzone, cinoxate, dioxybenzotie homosalate rnenthyl anthranilate, oetoerylene, octyl methoxycinnamate, octyl salicylate, oxybenzone, padimate O, phenylbenzimida ole sulfonic acid, sulisobenzone, titanium dioxide, trolamine salicylate, zinc oxide, 4- methyibenzylidene camphor, methylene bis-benzotriazolyi tetramethyibutylphenol, bis- eihyShexyloxyphenoi methox henyl triazine, terephthalyiideite dicamphor su!fonic acid, drometrizole trisiloxane, disodium phenyl dibenziroidazole tetra
- Suitable fragrances and colors may be used in the formulations of the present invention.
- Examples of fragrances and colors suitable for use in topical products are known in the art.
- Suitable inimunomodulators include, but are not limited to, tetrachlorodecaoxide, deoxycholic acid, tacrolimus, pimecraiimits, and bcta-glucan.
- paimitoyl-lysyl-valyMysioe bistrifiuoroacetate is added. This peptide stimulates collagen synthesis in human fibroblasts.
- one constituent of a composition may accomplish several functions.
- the present invention relates to constituents that may act as a lubricant, an emollient, or a skin-penetrating agent.
- the multi-functional constituent is socet l stearate, isopropyi isostearate, isopropyi palmitate, or isopropyi myristate.
- IL-37 is a potent inhibitor of immunity by keeping the cytokine equilibrium from excessi ve inflammation, and it showed broad inhibitory properties in the innate inflammatory and adaptive immune responses.
- IL-37 is a potent inhibitor of immunity by keeping the cytokine equilibrium from excessi ve inflammation, and it showed broad inhibitory properties in the innate inflammatory and adaptive immune responses.
- IL-37 is a potent inhibitor of immunity by keeping the cytokine equilibrium from excessi ve inflammation, and it showed broad inhibitory properties in the innate inflammatory and adaptive immune responses.
- the invention relates to the treatment of inflammatory skin conditions, including acne, actinic keratosis, chemical burn, contact dermatitis, bacterial infection, dermatitis, electrical bums, eczema, folliculitis, fungal infection, hives, photoaging, pityriasis rosea, poison ivy, psoriasis, pyoderma gangrenosum, radiation bum, rosacea, seborrhoeic eczema, sunburn, thermal bum, viral infection, and yeast infection.
- ultraviolet CUV ultraviolet CUV
- Exogenous 1L- 37 can reduce the production of 1L-6 and 1L-8 by keratinocytes, and thus, exogenous IL-37 can be administered to treat, prevent, or delay the onset of skin condition caused by UV radiation.
- exogenous 1L-3? attenuates cytokine secretion by modulating NF B phosphorylation and ER signaling ( Figure 4),
- Exogenous IL-37 reduces Propiomhact rium aems-mdn td IL-6 and 1L-8 secretion in keratinocytes (figure 2). Therefore, in some aspects, the invention relates to methods of treating, inhibiting, or preventing bacterial infections caused by Ptoptonih cierUtm by administering an effective amount of iti.terleukin-37, or a biologically active portion thereof in other aspects, the invention relates to methods of treating, inhibiting, or preventing bacterial infections caused by P. acnes by administering an effective amoun t of iiiterieukin- 37, or a biologically acti ve portion thereo P. acnes causes acne. Thus, the invention provides methods of treating, inhibiting, or preventing acne by administering an effective amount of interteukin-37, or a biologically active portion thereof.
- the invention relates to methods of treating, inhibiting, or preventing bacterial infections by administering an effective amount of interleukm-37, or a biologically active portion thereof.
- the invention relates to methods of treating, inhibiting, or preventing UV-hiduced skin damage, by administering an effective amount of intcrlcukin-37, or a biologically active portion thereof,
- the invention relates to methods of treating, inhibiting, or preventing psoriasis, by administering an effective amount of interieukm-37, or a biologically acti ve portion thereof.
- the invention relates to methods of treating skin conditions by
- the invention relates to a method of inhibiting or preventing fibrosis (such as formation of scar tissue) in a patient, comprising administering interieukin- 37 or a biologically acti ve portion thereof to the patient.
- the in vention relates to a method of treating a wound in a patient, comprising administering tnterieukin-37 or a biological ly active portion thereof to the patient.
- the administration of IL-37 may be topical, transdermal, oral, sublingual ; , intradermal, subcutaneous, intravenous, intramuscular, intraperitoneal, or inhalation.
- administration is topical, transdermal, oral, intradermal, or subcutaneous, in more preferred embodiments, administration is topical.
- a topical composition comprising IL-37 (or a biologically acti ve portion thereof) may comprise, for example, a dermatologicaily acceptable carrier or exe pient and mterleukin-37 (or a biologically active portion thereof), in some embodiments, the method comprises administering an effective amount- of i.L- 1 8B.PA, or a biologically active portion thereof.
- administering comprises applying IL-37 (such as a compositioii comprising IL-37) to an area of skin.
- the invention relates to a topical medicament, comprising a derraatologicaliy acceptable carrier or excipient and inierleukin-37, or a biologically active portion thereof.
- the topical medicament may further comprise IL-18.BPa, or a biologically active portion thereof.
Abstract
Some aspects of the invention relate to methods for treating, inhibiting, or preventing various skin conditions in a patient, comprising administering interleukin-37, or a biologically active portion thereof, to the patient. Some embodiments of the invention relate to topical medicaments comprising a dermatologically acceptable carrier or excipient and interleukin-37, or a biologically active portion thereof.
Description
Government interest
Tilts invention, was made with Government support under AR0S3542, awarded by the National Institutes of Health. The Government has certain rights in the invention. This work was supported by the U.S. Department of Veterans Affairs, and the Federal
Government has certain rights in the invention.
Priority Claim
This application claims the benefit: of priority to U.S. Provisional Patent Application
No. 61/979,389, filed on April 14, 2014, which is hereby incorporated by reference in its entirety.
Background
As the largest, organ, human skin provides the first line of defense against microbial pathogen-associated molecular patterns (PAMP) and physical and chemical damage- associated molecular patterns (DAMP). Ultraviolet (UV) irradiatioii has profound effects on hitman skin, causing sunburn, inflammation, cellular-tissue injury, photoaging and skin cancer. Most of these effects are mediated by proinflammatory cytokines produced by keratinocytes, such as l.L-6 and iL- .
Summary
Some aspects of the inventio relate to methods for treating, inhibiting, or
preventing various skin conditions in a patient, comprising administering interleukin-37, or a biologically active portion thereof, to the patient. Some embodiments of the invention relate to topical medicaments comprising a dermatologieally acceptable carrier or excipient and interleukin-37, or a biologically active portion thereof
Brief Description of the Figures
Figure 1 includes four panels, labeled panels (A), (B), (C), and (D). Panel (A) shows that IL-37 is induced in skin cells by P. acnes. Panel (B) shows that the immortalized human keraiiiiocvte ceil line HaCaT displays higher expression levels of IL-37 than monocytes in
cytosol. Panel (C) shows that IL-37 is activated b F. acnes infection. Panei (D) shows that IL-37 is expressed at higher level in acnes lesions.
Figure 2 shows that exogenous IL-37 attenuates P. acnes-induced inflammation in the immortalized human keratinoeyte cell line HaCaT, and figure 2 includes three panels, labeled panels (A), (B), and (C). Panel (A) shows that P. acnes induced IL-6 expression in HaCaT in a dose dependent manner, Panei (B) shows that exogenous IL-37 reduces P. acnes-'mduecd IL-6 secretion in HaCaT. Panel (C) shows thai exogenous IL-37 reduced P. a jey-induced IL-8 secretion in HaCaT.
Figure 3 shows the anti-inflammatory effects of IL-37 on UVB-induced HaCaT cells, and figure 3 includes four panels, labeled panels (A), (B)„ fC), and (D). Panel (A) shows that UVB induces IL-6 secretion in HaCaT i a dose dependent manner. Panel (B) shows that UVB down-regulates IL-37 expression. Panel (C) shows that exogenous IL-37
compensated to reduce UVB-induced iL-6 secretion. Panel (D) shows that IL-37 ameliorates inflammation under the different doses of UVB.
Figure 4 shows that exogenous IL-37 attenuates . acnes- and UVB- induced IL-6 secretion by modulating NFKB p65 phosphorylation and ER signaling pathway, and figure 4 includes three panels, labeled panels (A), (B), and (C). Panel (A) shows that IL-37 reduces the phosphorylation of NFtcB p 5 and E K2. Panel (B) shows that IL-37 reduces the phosphorylation of NFKB p65 and ERK2 induced by P. acnes. Panel (C) shows that IL- 37 reduces the phosphorylation of NFKB p65 and ERK2 induced by UVB radiation.
Figure 5 shows that IL-18Rp and l'L-i8B'Pa are involved in exogenous IL-37 attenuated inflammation induced by UVB and P. acnes, and figure 5 includes three panels, labeled panels (A), (B), and (C). Panel (A) shows that IL-37 anti-inflammatory properties are dependent on IL-18Rf}. Panel (B) shows that IL-37 and l'L-18BPa additively inhibit IL-6 secretion induced by U B. Panel (C) shows that l'L-37 and IL-1 SBPa down-regulate IL-6 secretion induced by P. acnes.
Detailed Description
Overview
The balance of inflammatory and anti-inflammatory responses is critical to maintain immune homeostasis in skin. IL-37 is a potent: inhibitor of immunity by keeping the cytokine equilibrium from excessi ve inflammation, and it has shown broad inhibitory properties in the innate inflammatory and adaptive immune responses.
IL-37 is a natural suppressor of innate inflammatory and immune responses. It serves as a dual-function cytokine with both intracellular and exiraceiiuiar mechanisms of action (Biila i A.M., et a!,, Proc. Natl Acad. Sci. U.S.A., 1 i 1(7):2650 (2034)).
IL-37 is absent in mice, but mice that express huma IL-37 are protected from lipopolysaccharide(LPS)-iiidu:ced shock, and showed markedly improved lung and kidney function and reduced liver damage after exposure to LPS ( okl M.F., et Nature Medicine, 1 1(1 1 ) : 1014 (2010)). Additionally, IL-37 plays a key role in intestinal inflammation because IL-37 expression protects mice from colitis (McNamee E.N., Proc. Natl Acad. Sci. U.S.A., 108(40): 1,671 1 (201 1».
In vivo expression of human iL-37 in mice reduces local and systemic inflammation in ConA-indueed hepatitis and LPS challenge (Bulau A.M., et at, Set. World. J., 1 1 :2480 (20.1 1 ); Sakai ., et a/. , J. Gastroenterol. Hepatol., 27(1): 1609 (201.2)). Additionally, IL-37 is involved in the pathophysiology of inflammatory bowel disease (IBD) as an antiinflammatory cytokine, and it is an inhibitor of both innate and acquired immune responses (!maeda H., et ah, Clin. Exp. Immunol., 172(3):4i0 (2013)). Further, IL-37 ameliorates the inflammatory process in psoriasis by suppressing pro-inflammatory cytokine expression (Teng ., J. Immunology, 192(4); 1815 (2014».
Although constantly assailed by stresses, the skin is not in a -perpetual state of inflammation. The processe underlying the skin's ability to keep inflammation subdued are not completely understood. IL-37, a member of the 11..- 1 famil of cytokines, has recently been shown to act as a potent inhibitor of inflammatory response. Skin tissue staining shows that IL-37 is present in high concentrations in epidermal keratinoeytes and in even higher quantities in chronic immune-mediated skin diseases, as psoriasis. As IL-37 is concentrated in the outer most layers of the skin, this cytokine may be important in the skin as a block to hyper reactive immunity. For example, the immortalized human keratmocyte cell line HaCaT does not actively secrete IL-37, but contains high cytosoiic concentrations of IL-37 (Figure l b). IL-37 is also an inducible cytokine as its gene expression increases at least 60% after treatment with P. acnes and UVB (p 0.05) and is upregulated in acne lesions (p<0.0 i ). The active spliced form of recombinant IL-37 inhibited UVB and P. acnes induction of T F-a, IL-Ιβ, and IL-6. This suggests that IL-37 has an anti-inflammatory role in response to damage- and pathogen-associated molecular patterns in keratinoeytes.
Some aspects of the invention relate to the use of interleukin-37 (IL-37) as a treatment for inflammatory and autoimmune conditions, cancers, and wound healing. IL-37 was recently identified as a member of the IL-1 family of cytokines. Experiments in transgenic mice demonstrate that IL-37 has a role as a naturally occurring anti- inflammatory cytokine; however, IL-37 has not yet been studied extensively in the context of humans and human diseases.
The results provided herein show that IL-37 has a significant role in the regulation of inflammation and would healing as a result of both pathogenic and damage-rela ted stimuli, including i'lOpio h t nm acnes infection and ultraviolet B radiation. Through immuRohistochemisiry, IL-37 was found to be expressed at high concentrations in the epidermis, and it is both expressed and translated by keratinocytes. While this data suggests that active IL-37 is not actively secreted b keratinocytes in high concentrations, the active protein is present in relati vely high concentrations intraccllularly in
keratinocytes. This data suggests that active IL-37, therefore, participates m paracrine signally after apoptosis or cell damage.
The use of recombinant IL-37 in the presence of both *. acnes infection and UVB radiation are able to significantly reduce the induction of pro-inflammatory cytokines, including IL-6, and decrease the activation of nuclear factor kappa b (NFKB) and mitogen- aetivated protein kinases signaling. These latter signaling pathways have been shown to be tremendously important in the regulation of turaorigenesis and immune regulation.
Furthermore, IL-37 significantly nioduiates the expression of matrix metailoprofeinase 3 in a direction that correlates with improved clinical outcomes of scarring.
Therefore, appropriate levels of recombinant IL-37 can be administered for the prevention and treatment of infectious and damage-induced inflammatory skin diseases, autoimmune diseases, cancers, and to improve outcomes of scarring and wound healing.
Definitions
As used herein the specification, "a" or "an" may mean one or more. As used herein in the ciaim(s), when used in conjunction with the word "comprising" , the words "a" or "an" may mean one or more than one. As used herein "another" may mean at least a second or more.
The term "IL-ISBPa" refers to DL-18 binding protein isoform a.
The term "prophylactic" or ''therapeutic'" treatment is art-recognized and includes administration to the host- of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic (i.e. , it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
The term "preventing" is art-recognized, and when used in relation to a condition such as a local recurrence (e.g., blemish), a disease such as acne or psoriasis, or an injury such as sunburn, is wel! understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of acne includes, for example, reducing the number of detectable blemishes (i.e. , lesions) in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable blemishes in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount, Preven tion of psoriasis includes, for example, reducing the magnitude and/or frequency of lesions experienced by subjects in a treated population versus an untreated control population. Prevention of a sunburn includes, for example, reducing the severit of a sunburn.
The term "radiation burn" re ers to tissue burns (esp, skin burns) caused by thermal radiation, radio frequency energy, microwaves, ultraviolet light, x-rays, ionizing radiation, gamma radiation.
The term '"sunburn" refers to tissue bums (esp, skin burns) caused by exposure to ultraviolet radiation.
A "therapeutically effective amount" of a compound with respec t to the subject method of treatment refers to an amount of the compound! s) in a preparation which, when administered as part of a desired dosage regimen {to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, eg,, at a reasonable benefit/risk ratio applicable to any medical treatment.
As used herein, the term "'treating" or "treatment* includes reversing, reducing, or arresting die symptoms, clinical signs, and underlying pathology of a condition in a manner to improve or stabilize a subject's condition. Exemplary Co tittjenis of Formulations
Exemplary identities of various constituents of the topical formulations of some embodiments of the present invention are described be!ow,
1 . Vehicles. Solvents, and Dil ents
Suitable topical vehicles and vehicle components for use with the formulations of the invention are well known in the cosmetic and pharmaceutical arts, and include such vehicles (or vehicle components) as water; organic solvents such as alcohols (particularly lower alcohols readily capable of evaporating from the skin such as ethanol), glycols (such as propylene glycol, butylenc glycol, and glycerol (glycerin)), aliphatic alcohols (such as lanolin); mixtures of water and organic solvents (such as wa ter and alcohol ), and mixtures of organic solvents such as alcohol and glycerol (optionally also with water); lipid-based materials such as fatty acids, acylglycerols (including oils, such as mineral oil, and fats of natural or synthetic origin), phosphogSycerides, sphingoiipids and waxes; protein- based materials such as collagen and gelatin; si!icone-based materials (both non-volatile and volatile) such as cyclomediicone, dimediiconol, di ethieone. and dimethieone copolyol; hydrocarbon-based materials such a petrolatum and squalane; and other vehicles and vehicle components that arc suitable for administration to the skin, as well as mixtures of topical vehicle components as identified above or otherwise known to the art
In one embodiment, the compositions of the present invention are oil-in- water emulsions. Liquids suitable for use in formulating compositions of the present invention include water, and water-miscible solvents such as glycols (e.g. , ethylene glycol, butylene glycol, isoprene glycol, propylene glycol), glycerol, liquid po!yols, dimethyl sulfoxide, and isopropyl alcohol One or more aqueous vehicles may be present.
In one embodiment, formulations without methanol, ethanol, propanols, or butano!s are desirable.
.2, Surfactants and Emnlsifiers
Many topical formulations contain chemical emulsions which use surface active ingredients (emuistfiers and surfactants) to disperse dissimilar chemicals in a particular solvent system. For example, most lipid-like (oily or fatty) or lipophilic ingredients do not
uniformly disperse in aqueous solvents unless they are first combined with eraulsifiers, which form microscopic aqueous soluble structures (droplets) that contain a lipophilic interior and a hydrophilic exterior, resulting in an oil-in-water emulsion. In order to be soluble in aqueous media, a molecule must be polar or charged so as to favorably interact with water molecules, which are also polar. Similarly, to dissolve an aqueous-soluble polar or charged ingredient in a largely lipid or oil-based solvent, an emulstfier is typically used which forms stable structures that contain the hydrophilic components in the interior of the structure while the exterior is lipophilic so that it can dissolve in the lipophilic solvent to form a water-io-oil emulsion. It is well known that such emulsions can be destabilized by the addition of salts or other charged ingredients which can interact with the polar or charged portions of the emulsifier within an emulsion droplet. Emulsion destabiiizatiort results in the aqueous and lipophilic ingredients separating into two layers, potentially destroying the commercial value of a topical product.
Surfactants suitable lor use in the present invention m y be ionic or non-ionic. These include, but are not limited to: ceryi alcohol, polysorbates (Polysorbate 20,
Polysorbate 40, Polysorbate 60, Polysorbate SO), steareth-10 (Brij 76), sodium dodecyl sulfate (sodium lauryl sulfate), lauryl dimethyl amine oxide, cety!trimethylamraooiura bromide (CTAB), polyethoxylated alcohols, polyoxyethylcne sorbitan, octoxynol, N,N- dimethyidodecylamine-N-oxide, feexadecyUrimethylammonium bromide (HTAB), polyoxyl 10 lauryl ether, bile salts (such as sodium deoxyeholate or sodium chelate), polyoxyl castor oil, nonylphenol ethox late, eyclodextrins, lecithin, dimethicone copolyol, lauramid© DEA, coeamide DBA, cocamide MEA, ofeyf betaine, cocamidopropyl betaine, cocamidopropyf phosphatidyl PG-dimonium chloride, dicetyi phosphate (dihexadecyi phosphate), ce.eare.h- 1 phosphate, methylbenzemonium chloride, dicetyi phosphate, ceteth-10 phosphate
('ceteth-10 is the polyethylene glycol ether of cetyl alcohol where » has art average value of 10; ceteth- 10 phosphate is a mixture of phosphoric acid esters of ceteth-1 ), eeteth-20, Brij S10 (polyethylene glycol octadecyl ether, average Mn ~ 71 1), and Poioxamers (including, but not limited to, Poloxaracr 188 (HO(C2H4O CH(C¾)CH20 C2H40')aH5 average molecular weight 8400) and Poloxaracr 407 {HO(C2¾0)a(CH(CH;; CH20 b(C2H40)aH, wherein a is about 101 and h is about 56)). Appropriate combinations or mixtures of such surfactants may also be used according to the present invention.
Many of t hese surfactants may also serve as emulsifiers in formulations of the present invention.
Other suitable emu!stfiers for use in the formulations of the present invention include, but are not limited to, behentrimonium methositlfate-cetearyi alcohol, non-ionic emii!sifiers !ike emulsifying wax, polyoxyethylene oleyl ether, PEG-40 stearate, eetostearyl alcohol (cetearyl alcohol), ceteareth-12, ceteareth-20, eeteareth~30, ceteareth alcohol, Ceteth-20 (Ceteth-20 is the poly ethylene glycol ether of cetyl alcohol where n has an average value of 20), oleic acid, oie i alcohol, glyceryl stearate, PEG-75 stearate, PEG- 100 stearate, and PEG- 100 stearate, ceramide 2, ceramide 3, stearic acid, cholesterol, steareth-2, and steareth-20, or crmibinations/mixtures thereof, as well as cationie emulsifiers like stearamidopropyl diniethylamine and behentrimonium methosulfaie, or
combinations/mixtures thereof.
3. Moisturizers^ h-m° f.i 'Cfs .<* H¾mectants
One of the most important aspects of topical products in general, and cosmetic products in particular, is the consumer's perception of the aesthetic qualities of a product For example, while white petrolatum is an excellent moisturizer and skin protectant, it is rarely used alone, especially on the face, because it is greasy, sticky, does not rub easily into the skin and ma soil clothing. Consumers highly value products which are aesthetically elegant and have an acceptable tactile feel and performance on their skin.
Suitable moisturizers for use in the formulations of the present invention include, but are not limited to, lactic acid and other hydroxy acids and their salts, glycerol, propylene glycol, butyiene glycol, sodium PCA, sodium hyaluronate, Carbowax 200, Carbo ax 400, and Carbowax 800,
Suitable emollients or humeetaiits for use in the formulations of the present invention include, but are not limited to, panthenol, cetyl palmitate, glycerol (glycerin), PPG-15 stearyl ether, lanolin alcohol, lanolin, lanolin derivatives, cholesterol, petrolatum, isostearyS neoperttartoate, oetyl stearate, mineral oik isocetyl stearate, myristyi myristate, oetyl dodecanoL 2-ethylhexyi palmitate (oetyl palmitate), dimethieone, phenyl
trimethicone, cyclomethicone, Ct2-C}$ alkyi henzoates, dimethiconol, propylene glycol, hmhrom gr ndifio m seed butter, ceramides (e.g., ceramide 2 or ceramide 3),
hydroxypropyl bispalmitamide MEA, hydroxypropyl bislauramide MEA, hydroxypropvl bisisostearamide MEA, .1 !3-bis(N-2~(hydroxyethyl)stearoylamino)-2 -hydroxy propane, bis* hydroxyethyi tocopherylsuccmoylaroido hydroxypropane, urea, aloe, allantoin,
giycyrrhetinic acid, safllower oil, olcyl alcohol, oleic acid, stearic acid.
dicapryiate/dicaprate,, diethyl sehacate, isostearyl alcohol, pentylene glycol, isononyi isononanoate, and l,3-bls(N~2-(hydroxyethy1)palmuoylamino)-2-hydroxypropane.
In addition, appropriate combinations and mixtures of any of these moisturizing agents and emollients may be used in accordance with the present invention.
4. Preservatives and Antioxidants
The composition may further include components adapted to improve the stability or effectiveness of the applied formulation.
Suitable preservatives for use in the present invention include, but are not limited to: ureas, such as i idazolidinyi urea and diazotidioyl urea; phenoxyeihanoi; sodium methyl parahen, methy!paraben, ethylparaben, and propylparaben; potassium sorbate; sodium benzoate; sorbic acid; benzoic acid; formaldehyde; citric acid; sodium citrate; chlorine dioxide; quaternary ammonium compounds, such as benzalkomum chloride, benzethonium chloride, eetrimidc, deqimhn um chloride, and eetyipyridinium chloride; mercurial agents, such as phenylmereurie nitrate, phenylmereurie acetate, and thimerosal; piroctone olamine; Viiis vinifem seed oil; and alcoholic agents, for example, chlorobutanol, dichlorobenzyl alcohol phenylethyl alcohol, and benzyl alcohol
Suitable antioxidants include, but are not limited to, ascorbic acid and its esters, sodium bisulfite, butylatcd hydroxytoluene, buty!ated hydroxyamsole, tocopherols, tocophetyi acetate, sodium ascorbaie/ascorbic acid, ascorbyi palmitate, propyl galiate, and chelating agents like EDTA (e.g. , disodium EDTA), citric acid, and sodium citrate.
i certain embodiments, the antioxidant or preservative comprises (3-(4- chlorophenoxy)-2-hydroxypropyl carbamate.
In certain embodiments, antioxidants or preservatives of the present invention may also function as a moisturizer or emollient, for example.
in addition, combinations or mixtures of these preservatives or anti-oxidants may also be used in the formulations of the present invention.
5. Combination agents
The composition can also contain any other agent that has a desired effect when applied topically to a mammal, particularly a human. Suitable classes of active agents include, but are not limited to, antibiotic agents, antimicrobial agents, anti-acne agents, antibacterial agents, antifungal agents, antiviral agents, steroidal anti-inflammatory agents, non-steroidal anti-inflammatory agents, anesthetic agents, antipiitriginous agents, antiprotozoal agents, anti-oxidants, antihistamines, vitamins, and hormones. Mixtures of
an of these active agents may also be employed Additionally, dermatoiogicaliy-acceptable sails and esters of any of these agents may be employed.
6. Buffer Salts
Suitable buffer sails are well-known in the art. Examples of suitable buffer salts include, but are not limited to sodium: citrate, citric acid, sodium phosphate monobasic, sodium phosphate dibasic, sodium phosphate tribasic, potassium phosphate monobasic, potassium phosphate dibasic, and potassium phosphate tribasic.
7. Viscosity Modifiers
Suitable viscosity adjusting agents (i.e., thickening and thinning agents or viscosity modifying agents) for use in the formulations of the present invention include, but are not limited to, protective colloids or non-ionic gums such as hydroxyethyleeiluiose, xanthan gum, and sclerotiura gum, as well as magnesium aluminum: silicate, silica, macrocrystalline wax, beeswax, paraffin, and cetyl palmitate. in addition, appropriate combinations or mixtures of these viscosity adjusters may be utilized according to the present invention.
Additional constituents suitable for incorporation into the emulsions of the present invention include, but are not limited to: skin protectants, adsorbents, demulcents, emollients, moisturizers, sustained release materials, solubilizing agents, skin-penetration agents, skin soothing agents, deodorant agents, antiperspirants sun screening agents, sunless tanning agents, vitamins, hair conditioning agents, anti-irritants, anti-aging agents, abrasives, absorbents, auti-caking agents, anti-static agents, astringents (e.g.. witch hazel, alcohol, and herbal extracts such as chamomile extract), bmders/excipiems, buffering agents, chelating agents, film forming agents, conditioning agents, opacifying agents, lipids, immunomodulators, and pH adjusters (e.g., citric acid, sodium hydroxide, and sodium phosphate).
For example, lipids normally found in healthy skin (or their functional equivalents) may be incorporated into the emulsions of the present invention, in certain embodiments, the Itpid is selected from the group consisting of ceramtdes, cholesterol, and free fatty acids. Examples of lipids include, but arc not limited to, eeramide 1, ceramide 2, eeramide 3, eeramide 4, eeramide 5, eeramide 6, hyd oxypropyl bispa.hnitam.ide MEA, and
hydroxy-propyl bislauramide MBA, and combinations thereof.
Examples of peptides that interact with protein structures of the dermal-epidermal junction include paimitoyl dipeptide-5 diaminohutyloyl hydro y threonine and paimitoyl dipeptide-6 diaim'nohydroxybutyrate.
Examples of skin soothing agents include, but are not limited to algae extract, mugwort extract, stearyi glycyrrhetinate, bisabolol, allantoic aloe, avocado oik green tea extract, hops extract, chamomile extract, colloidal oatmeal, calamine, cucumber extract, and combinations thereof.
in certain embodiments, the compositions comprise bergamot or bergamot oil. Bergamot oil is a natural skin toner and detoxtiier. In certain embodiments, it may prevent premature aging of skin and may have excellent effects on oily skin conditions and acne.
Examples of vitamins include, but are not limited to, vitamins A, ΪΧ E, K, and combinations thereof. Vitamin analogues are also contemplated; for example, the vitamin D analogues eaieipotnene or caicipotriol.
i certain embodiments, the vitamin may be present as teirahexyldecyS ascorbate. This compound exhibits antioxidant activity, inhibiting lipid peroxidation, hi certain embodiments, use can mitigate the damaging effects ofUV exposure. Studies have shown it to stimulate collagen production as well as clarifying and brightening the skirt by inhibiting meianogenesis (the -production of pigment) thereby promoting a more even skin tone.
Examples of sunscreens include, but are not limited to, p-aramobmzoic acid, avobenzone, cinoxate, dioxybenzotie homosalate rnenthyl anthranilate, oetoerylene, octyl methoxycinnamate, octyl salicylate, oxybenzone, padimate O, phenylbenzimida ole sulfonic acid, sulisobenzone, titanium dioxide, trolamine salicylate, zinc oxide, 4- methyibenzylidene camphor, methylene bis-benzotriazolyi tetramethyibutylphenol, bis- eihyShexyloxyphenoi methox henyl triazine, terephthalyiideite dicamphor su!fonic acid, drometrizole trisiloxane, disodium phenyl dibenziroidazole tetrasuifbnate, diethviamino hydroxybenzoyl hexyl benzoaie, octyl triazone, diethylhexyl butamido triazone, polysilieone~15, and combinations thereof.
Suitable fragrances and colors ma be used in the formulations of the present invention. Examples of fragrances and colors suitable for use in topical products are known in the art.
Suitable inimunomodulators include, but are not limited to, tetrachlorodecaoxide, deoxycholic acid, tacrolimus, pimecraiimits, and bcta-glucan.
In certain embodiments, paimitoyl-lysyl-valyMysioe bistrifiuoroacetate is added. This peptide stimulates collagen synthesis in human fibroblasts.
Often, one constituent of a composition may accomplish several functions. In one embodiment, the present invention relates to constituents that may act as a lubricant, an emollient, or a skin-penetrating agent. In one embodiment, the multi-functional constituent is socet l stearate, isopropyi isostearate, isopropyi palmitate, or isopropyi myristate.
.Exemplary Uses
Normal skin cells express low levels o IL-37. As shown herein, IL-37 is a potent inhibitor of immunity by keeping the cytokine equilibrium from excessi ve inflammation, and it showed broad inhibitory properties in the innate inflammatory and adaptive immune responses. One of ordinary skill in the art will appreciate that various inflammatory conditions can be treated, prevented, or their onset delayed by administering IL-37. in particular, the invention relates to the treatment of inflammatory skin conditions, including acne, actinic keratosis, chemical burn, contact dermatitis, bacterial infection, dermatitis, electrical bums, eczema, folliculitis, fungal infection, hives, photoaging, pityriasis rosea, poison ivy, psoriasis, pyoderma gangrenosum, radiation bum, rosacea, seborrhoeic eczema, sunburn, thermal bum, viral infection, and yeast infection. Additionally, ultraviolet CUV) irradiation has profound effects on human skin, causing sunburn, inflammation, cellular- tissue injury, photoaging and skin cancer. Most of these effects are mediated b proinflammatory cytokines produced by keratinocytes, such as 1L-6 and lL-8, Exogenous 1L- 37 can reduce the production of 1L-6 and 1L-8 by keratinocytes, and thus, exogenous IL-37 can be administered to treat, prevent, or delay the onset of skin condition caused by UV radiation. Specifically, exogenous 1L-3? attenuates cytokine secretion by modulating NF B phosphorylation and ER signaling (Figure 4),
Exogenous IL-37 reduces Propiomhact rium aems-mdn td IL-6 and 1L-8 secretion in keratinocytes (figure 2). Therefore, in some aspects, the invention relates to methods of treating, inhibiting, or preventing bacterial infections caused by Ptoptonih cierUtm by administering an effective amount of iti.terleukin-37, or a biologically active portion thereof in other aspects, the invention relates to methods of treating, inhibiting, or preventing bacterial infections caused by P. acnes by administering an effective amoun t of iiiterieukin- 37, or a biologically acti ve portion thereo
P. acnes causes acne. Thus, the invention provides methods of treating, inhibiting, or preventing acne by administering an effective amount of interteukin-37, or a biologically active portion thereof.
As practitioners with ordinary skill in the art will recognize, treatment of P. acnes correlates with the treatment of other bac terial infections of the skin.. Therefore, in some aspects, the invention relates to methods of treating, inhibiting, or preventing bacterial infections by administering an effective amount of interleukm-37, or a biologically active portion thereof.
Ultraviolet B radiation reduces the expression of IL-37 in keratinocytes. Exogenous IL-37, however, compensates for UVB-induced IL-37 downregulation and reduces UVB- indueed lL-6 secretion (Figure 3). Thus, in some aspects, the invention relates to methods of treating, inhibiting, or preventing UV-hiduced skin damage, by administering an effective amount of intcrlcukin-37, or a biologically active portion thereof,
IL-37 is highly expressed in psoriasis lesions. cratinoeytes, however, do not actively secrete IL-37. Therefore, in some aspects, the invention relates to methods of treating, inhibiting, or preventing psoriasis, by administering an effective amount of interieukm-37, or a biologically acti ve portion thereof.
IL-37 and IL~ I 8BPa additive!y inhibit IL-6 secretion by keratmoevtes. Therefore, in some aspects, the invention relates to methods of treating skin conditions by
administering an effective amount of IL-37 and IL18Bpa.
In some embodiments, the invention relates to a method of inhibiting or preventing fibrosis (such as formation of scar tissue) in a patient, comprising administering interieukin- 37 or a biologically acti ve portion thereof to the patient.
in some embodiments, the in vention relates to a method of treating a wound in a patient, comprising administering tnterieukin-37 or a biological ly active portion thereof to the patient.
'The administration of IL-37 may be topical, transdermal, oral, sublingual;, intradermal, subcutaneous, intravenous, intramuscular, intraperitoneal, or inhalation. In preferred embodiments, administration is topical, transdermal, oral, intradermal, or subcutaneous, in more preferred embodiments, administration is topical. A topical composition comprising IL-37 (or a biologically acti ve portion thereof) may comprise, for example, a dermatologicaily acceptable carrier or exe pient and mterleukin-37 (or a biologically active portion thereof), in some embodiments, the method comprises
administering an effective amount- of i.L- 1 8B.PA, or a biologically active portion thereof. n some embodiments, administering comprises applying IL-37 (such as a compositioii comprising IL-37) to an area of skin.
In some embodiments, the invention relates to a topical medicament,, comprising a derraatologicaliy acceptable carrier or excipient and inierleukin-37, or a biologically active portion thereof. The topical medicament may further comprise IL-18.BPa, or a biologically active portion thereof.
Incorporation by Reference
All patents, published patent applications, and other publication mentioned irt the description above are incorporated by reference herein in their entirety.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims
1 . A method of treating, inhibiting, or preventing UV-induced skin damage in a patient, comprising administering inter!eukin-37 or a biologically active portion thereof to the patient.
2. A method of treating, inhibiting, or preventing a skin condition in a patient, comprising administering inter!eukin-37 or a biologically active portion thereof to the pattent.
3. The method of claim 2, wherein said skin condition is acne, actinic keratosis, chemical bum, contact dermatitis, bacterial infection, dermatitis, electrical bums, eczema, folliculitis, fungal infection, hives, photoaging, pityriasis rosea, poison ivy, pyoderma gangrenosum., radiation burn, rosacea, seborrhoeie eczema, sunburn, thermai burn, viral infection, or yeast infection.
4. The method of claim 2, wherein said skin condition is acne,
5. The method of claim 2, wherein said skin condition is caused by a bacterial infection.
6. The method of claim 5, wherein said bacterial infection is caused by
.Propionibactetit .
7. The method of claim: 5, wherein said bacterial infection is caused by
Propionibacierium ucucs.
8. The method of claim 2, wherein said skin condition is radiation born.
9. The method of claim 2, wherein said skin condition is sunburn.
10. A method of inhibiting or preventing fibrosis (such as formation of scar tissue) in a patient, comprising administering iriterleukin-37 or a biologically active portion thereof to the patient,
1 i , A method of treating a wound in a patient, comprising administering interlcukm-3? or a biologically active portion thereof to the patient.
1.2. The method of any preceding claim, wherein the administering i topical, transdermal, oral, sublingual, intradermal, subcutaneous, intravenous, intramuscular, intraperitoneal, or inhalation.
13. The method of any preceding claim, wherein the administering is topical,
transdermal, oral, intradermal, or subcutaneous.
14. The method of any preceding claim, wherein administering comprises applying to an area of skin.
15. The method of any preceding claim, further comprising administering an effective amount of IL- S BPa.
16. A topical medicament, comprising a dermatologicaHy acceptable carrier or excipiertt and interleukin-37 or a biologically active portion thereof.
17. The topical medicament of claim 16, further comprising iL- l 8BPa or a biologically active portion thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461979389P | 2014-04-14 | 2014-04-14 | |
US61/979,389 | 2014-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015160795A1 true WO2015160795A1 (en) | 2015-10-22 |
Family
ID=54324492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/025730 WO2015160795A1 (en) | 2014-04-14 | 2015-04-14 | Compositions and methods for treating inflammation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015160795A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140004128A1 (en) * | 2010-12-20 | 2014-01-02 | Medimmune Limited | Anti-il-18 antibodies and their uses |
-
2015
- 2015-04-14 WO PCT/US2015/025730 patent/WO2015160795A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140004128A1 (en) * | 2010-12-20 | 2014-01-02 | Medimmune Limited | Anti-il-18 antibodies and their uses |
Non-Patent Citations (4)
Title |
---|
FUJITA ET AL.: "Interleukin-37 is elevated in subjects with atopic dermatitis", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 69, no. 2, 2013, pages 173 - 176 * |
HARSKAMP ET AL.: "Immunology of atopic dermatitis: novel insights into mechanisms and immunomodulatory therapies", SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, vol. 32, no. 3, 2013, pages 132 - 139, XP055230727 * |
JENSEN: "'Targeting the IL-1 family members in skin inflammation'", CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 11, no. 11, 2010, pages 1211 - 1220, XP055230729 * |
TENG ET AL.: "IL -37 ameliorates the inflammatory process in psoriasis by suppressing proinflammatory cytokine production", THE JOURNAL OF IMMUNOLOGY, vol. 192, no. 4, 22 January 2014 (2014-01-22), pages 1815 - 1823 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0633017B1 (en) | Cosmetic and dermatologic compositions containing delta-aminolevulinic acid | |
US10232047B2 (en) | Topical oil composition for the treatment of fungal infections | |
US20050069566A1 (en) | Foam carrier containing amphiphilic copolymeric gelling agent | |
US20060193789A1 (en) | Film forming foamable composition | |
US20050232869A1 (en) | Nonsteroidal immunomodulating kit and composition and uses thereof | |
DE4420625C1 (en) | Active substance combination with a content of glycerylalkyl ethers and cosmetic and dermatological preparations containing such active substance combinations | |
US20030170199A1 (en) | Cosmetic and/or dermatological composition based on cocoa extracts | |
US10532024B2 (en) | Topical compositions of Lithospermum erythrorhizon (gromwell root) for treating or controlling excessive oil production in skin and minimizing glycation in skin, and methods of using the compositions | |
KR101443927B1 (en) | Composition containing a class of hexamidine and a class of retinoid for improving skin condition | |
EP1996153B1 (en) | Use of glycyrrhetic acid and/or glycyrrhizin for producing compositions for tanning the skin | |
US20130189196A1 (en) | Foamable Composition | |
EP3030229B1 (en) | Anti-acne compositions comprising bile acid-fatty acid conjugates | |
AU2018238691A1 (en) | Pharmaceutical compositions | |
DE4305788C2 (en) | Cosmetic and dermatological formulations to protect the skin against oxidation processes | |
KR102587297B1 (en) | A composition for preventing or treating sleep disturbance | |
EP3030221A1 (en) | Anti-aging compositions comprising bile acid-fatty acid conjugates | |
JPH06503085A (en) | new composition | |
ES2634423T3 (en) | Skin treatments containing idebenone derivatives substituted with carboxylic acid and methods of preparation and use thereof | |
CA2822746A1 (en) | Compositions and methods for treatment of vitiligo | |
DE10352367A1 (en) | Treatment of rosacea using licochalcone A or extracts of Radix Glycyrrhizae inflatae, provides long-lasting suppression of redness and inhibits further outbreaks | |
WO2015160795A1 (en) | Compositions and methods for treating inflammation | |
EP2090296B1 (en) | Application of agent complexes composed of panthenol, glycerin, citrate and/or bisabal oil against pollen allergy | |
US8491946B2 (en) | Elastase inhibitor | |
DE4405585C2 (en) | Use of trans-urocanic acid for the treatment or prophylaxis of oxidative stress induced skin aging | |
US20080019957A1 (en) | Topically applied probucol-containing agent with protective and regenerative effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15780129 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15780129 Country of ref document: EP Kind code of ref document: A1 |